Understanding protein arginine methyltransferase 1 (PRMT1) product specificity from molecular dynamics

Symon Gathiaka, Brittany Boykin, Tamar Cáceres, Joan M. Hevel, Orlando Acevedo

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Protein arginine methyltransferases (PRMTs) catalyze the post-translational methylation of specific arginyl groups within targeted proteins to regulate fundamental biological responses in eukaryotic cells. The major Type I PRMT enzyme, PRMT1, strictly generates monomethyl arginine (MMA) and asymmetric dimethylarginine (ADMA), but not symmetric dimethylarginine (SDMA). Multiple diseases can arise from the dysregulation of PRMT1, including heart disease and cancer, which underscores the need to elucidate the origin of product specificity. Molecular dynamics (MD) simulations were carried out for WT PRMT1 and its M48F, H293A, H293S, and H293S-M48F mutants bound with S-adenosylmethionine (AdoMet) and the arginine substrate in an unmethylated or methylated form. Experimental site-directed mutagenesis and analysis of the resultant products were also performed. Two specific PRMT1 active site residues, Met48 and His293, have been determined to play a key role in dictating product specificity, as: (1) the single mutation of Met48 to Phe enabled PRMT1 to generate MMA, ADMA, and a limited amount of SDMA; (2) the single mutation of His293 to Ser formed the expected MMA and ADMA products only; whereas (3) the double mutant H293S-M48F-PRMT1 produced SMDA as the major product with limited amounts of MMA and ADMA. Calculating the formation of near-attack conformers resembling SN2 transition states leading to either the ADMA or SDMA products finds that Met48 and His293 may enable WT PRMT1 to yield ADMA exclusively by precluding MMA from binding in an orientation more conducive to SDMA formation, i.e., the methyl group bound at the arginine Nη2 position.

Original languageEnglish (US)
Pages (from-to)4949-4960
Number of pages12
JournalBioorganic and Medicinal Chemistry
Volume24
Issue number20
DOIs
StatePublished - Oct 15 2016

Fingerprint

Protein-Arginine N-Methyltransferases
Molecular Dynamics Simulation
Molecular dynamics
Arginine
S-Adenosylmethionine
Mutagenesis
Mutation
Heart Neoplasms
Methylation
Eukaryotic Cells
Site-Directed Mutagenesis
N,N-dimethylarginine
Heart Diseases
Catalytic Domain

Keywords

  • Computational
  • Molecular dynamics
  • Mutagenesis
  • Posttranslational methylation
  • Protein arginine methyltransferases

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Understanding protein arginine methyltransferase 1 (PRMT1) product specificity from molecular dynamics. / Gathiaka, Symon; Boykin, Brittany; Cáceres, Tamar; Hevel, Joan M.; Acevedo, Orlando.

In: Bioorganic and Medicinal Chemistry, Vol. 24, No. 20, 15.10.2016, p. 4949-4960.

Research output: Contribution to journalArticle

Gathiaka, Symon ; Boykin, Brittany ; Cáceres, Tamar ; Hevel, Joan M. ; Acevedo, Orlando. / Understanding protein arginine methyltransferase 1 (PRMT1) product specificity from molecular dynamics. In: Bioorganic and Medicinal Chemistry. 2016 ; Vol. 24, No. 20. pp. 4949-4960.
@article{24f4aff9612949bcb1e93b5bb2154904,
title = "Understanding protein arginine methyltransferase 1 (PRMT1) product specificity from molecular dynamics",
abstract = "Protein arginine methyltransferases (PRMTs) catalyze the post-translational methylation of specific arginyl groups within targeted proteins to regulate fundamental biological responses in eukaryotic cells. The major Type I PRMT enzyme, PRMT1, strictly generates monomethyl arginine (MMA) and asymmetric dimethylarginine (ADMA), but not symmetric dimethylarginine (SDMA). Multiple diseases can arise from the dysregulation of PRMT1, including heart disease and cancer, which underscores the need to elucidate the origin of product specificity. Molecular dynamics (MD) simulations were carried out for WT PRMT1 and its M48F, H293A, H293S, and H293S-M48F mutants bound with S-adenosylmethionine (AdoMet) and the arginine substrate in an unmethylated or methylated form. Experimental site-directed mutagenesis and analysis of the resultant products were also performed. Two specific PRMT1 active site residues, Met48 and His293, have been determined to play a key role in dictating product specificity, as: (1) the single mutation of Met48 to Phe enabled PRMT1 to generate MMA, ADMA, and a limited amount of SDMA; (2) the single mutation of His293 to Ser formed the expected MMA and ADMA products only; whereas (3) the double mutant H293S-M48F-PRMT1 produced SMDA as the major product with limited amounts of MMA and ADMA. Calculating the formation of near-attack conformers resembling SN2 transition states leading to either the ADMA or SDMA products finds that Met48 and His293 may enable WT PRMT1 to yield ADMA exclusively by precluding MMA from binding in an orientation more conducive to SDMA formation, i.e., the methyl group bound at the arginine Nη2 position.",
keywords = "Computational, Molecular dynamics, Mutagenesis, Posttranslational methylation, Protein arginine methyltransferases",
author = "Symon Gathiaka and Brittany Boykin and Tamar C{\'a}ceres and Hevel, {Joan M.} and Orlando Acevedo",
year = "2016",
month = "10",
day = "15",
doi = "10.1016/j.bmc.2016.08.009",
language = "English (US)",
volume = "24",
pages = "4949--4960",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "20",

}

TY - JOUR

T1 - Understanding protein arginine methyltransferase 1 (PRMT1) product specificity from molecular dynamics

AU - Gathiaka, Symon

AU - Boykin, Brittany

AU - Cáceres, Tamar

AU - Hevel, Joan M.

AU - Acevedo, Orlando

PY - 2016/10/15

Y1 - 2016/10/15

N2 - Protein arginine methyltransferases (PRMTs) catalyze the post-translational methylation of specific arginyl groups within targeted proteins to regulate fundamental biological responses in eukaryotic cells. The major Type I PRMT enzyme, PRMT1, strictly generates monomethyl arginine (MMA) and asymmetric dimethylarginine (ADMA), but not symmetric dimethylarginine (SDMA). Multiple diseases can arise from the dysregulation of PRMT1, including heart disease and cancer, which underscores the need to elucidate the origin of product specificity. Molecular dynamics (MD) simulations were carried out for WT PRMT1 and its M48F, H293A, H293S, and H293S-M48F mutants bound with S-adenosylmethionine (AdoMet) and the arginine substrate in an unmethylated or methylated form. Experimental site-directed mutagenesis and analysis of the resultant products were also performed. Two specific PRMT1 active site residues, Met48 and His293, have been determined to play a key role in dictating product specificity, as: (1) the single mutation of Met48 to Phe enabled PRMT1 to generate MMA, ADMA, and a limited amount of SDMA; (2) the single mutation of His293 to Ser formed the expected MMA and ADMA products only; whereas (3) the double mutant H293S-M48F-PRMT1 produced SMDA as the major product with limited amounts of MMA and ADMA. Calculating the formation of near-attack conformers resembling SN2 transition states leading to either the ADMA or SDMA products finds that Met48 and His293 may enable WT PRMT1 to yield ADMA exclusively by precluding MMA from binding in an orientation more conducive to SDMA formation, i.e., the methyl group bound at the arginine Nη2 position.

AB - Protein arginine methyltransferases (PRMTs) catalyze the post-translational methylation of specific arginyl groups within targeted proteins to regulate fundamental biological responses in eukaryotic cells. The major Type I PRMT enzyme, PRMT1, strictly generates monomethyl arginine (MMA) and asymmetric dimethylarginine (ADMA), but not symmetric dimethylarginine (SDMA). Multiple diseases can arise from the dysregulation of PRMT1, including heart disease and cancer, which underscores the need to elucidate the origin of product specificity. Molecular dynamics (MD) simulations were carried out for WT PRMT1 and its M48F, H293A, H293S, and H293S-M48F mutants bound with S-adenosylmethionine (AdoMet) and the arginine substrate in an unmethylated or methylated form. Experimental site-directed mutagenesis and analysis of the resultant products were also performed. Two specific PRMT1 active site residues, Met48 and His293, have been determined to play a key role in dictating product specificity, as: (1) the single mutation of Met48 to Phe enabled PRMT1 to generate MMA, ADMA, and a limited amount of SDMA; (2) the single mutation of His293 to Ser formed the expected MMA and ADMA products only; whereas (3) the double mutant H293S-M48F-PRMT1 produced SMDA as the major product with limited amounts of MMA and ADMA. Calculating the formation of near-attack conformers resembling SN2 transition states leading to either the ADMA or SDMA products finds that Met48 and His293 may enable WT PRMT1 to yield ADMA exclusively by precluding MMA from binding in an orientation more conducive to SDMA formation, i.e., the methyl group bound at the arginine Nη2 position.

KW - Computational

KW - Molecular dynamics

KW - Mutagenesis

KW - Posttranslational methylation

KW - Protein arginine methyltransferases

UR - http://www.scopus.com/inward/record.url?scp=84989172071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989172071&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2016.08.009

DO - 10.1016/j.bmc.2016.08.009

M3 - Article

VL - 24

SP - 4949

EP - 4960

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 20

ER -